← Back to headlines
Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy
Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.
22 May, 08:44 — 22 May, 08:44
Related Stories
DRC Launches Ebola Vaccination Campaign as UN Seeks $1.1 Billion in Funding
1h ago
Cyclospora Outbreak Linked to Iceberg Lettuce Expands to Three Additional States
4h ago
Australian Woman Gives Birth to Twins Fathered by Two Different Men
7h ago
U.S. FDA Approves Landmark Pancreatic Cancer Drug With Improved Survival Rates
11h ago